




2015

ANNUAL REVIEW



Introduction

Uppsala BIO is the operational arm and life science focus of 'STUNS' – the Foundation for Collaboration between the Universities in Uppsala, Business and the Public Sector. Its purpose is to strengthen the life science sector's long-term competitiveness and attractiveness. Getting more sustainable life science companies to grow in the region is the goal.


The industrial development of the region's life science sector was very strong during 2015. For example, Uppsala's largest private employer, GE Healthcare, announced an investment of 870 MSEK over three years in its production facility. Another company investing in increased manufacturing capacity is Galderma, who will increase production volume five-fold by 2024.

The Uppsala region has a well established ecosystem for life science: two universities, both of which have innovation offices; the business incubator UIC; support networks such as Uppsala BIO; a research infrastructure like SciLifeLab; a large university hospital with its own medical innovation department; and government authorities such as the Medical Products Agency, the National Veterinary Institute and the National Food Administration. The ecosystem also benefits from IT and consulting firms, an active business development unit within Uppsala Municipality as well as Scandinavia's leading law firm in the life science sector.



In June eight new life science projects receive two-year support in the call Smart ICT solutions for better healthcare and more effective treatment.

From the left: Pia Keyser, Brain Stimulation AB; Gunnar Dagnå and Anders Johnsson, EBP Solutions AB; Oliver Mohseni and Oliver Farshid, Genit AB; Jesper Hassel, Mevia; and Dina Titkova and Björn De Jounge, Biosync Technology AB.



Neurons forms connections with other neurons.

These connections, known as synapses, allow cells to rapidly share information, coordinate their activities, and achieve learning and memory. Uppsala BIO facilitates and supports coordination and integration of regional and national innovation support system as well as collaboration between projects/early start-ups and established industry.



NLSDays 2015. In Uppsala BIOs both you can among others see Anna Attefall, project leader Innovation Akademiska, Ylva Williams CEO Stockholm Science City Foundation, Jan Stålemark CEO Arocell with a colleague and Karin Agerman, project leader at Uppsala BIO.

Content

Completed activities	4
Innovation support activities	4
BIO-X Open	4
BIO-X Industry	5
SWElife	5
Networking activities	6
BIO-PUB	6
Efter Jobbet	6
Other events	6
Participation in boards and groups	7
International activities	7
Member activities	7
Educational activities	7
Presentations and seminars	7
Technical Collage	8
Regional activities	8
Uppsala Innovation Centre	8
Uppsala University Innovation	8
SLU Holding	8
Connect	9
Innovation Akademiska	9
REBUS	9
Investigations and other activities	9
Organisation	10
Board	10
Co-workers	10
Advisory boards	10
Economic analysis	11
Result	11
Participation in funding applications	11
Members and partners	12

Completed activities

Uppsala BIO shall contribute to the development of the life science sector in the region and strengthen its international competitiveness. To this end, it carried out a variety of activities during the year.

INNOVATION SUPPORT ACTIVITIES

Uppsala BIO's innovation support activities are based on the methodology developed within the framework of the innovation program BIO-X, one of the core activities within Uppsala BIO. In 2015, seven newly-started companies participated in Uppsala BIO-sponsored activities, including six in BIO-X. In addition, three new processes started up with Uppsala BIO's participation.

BIO-X OPEN

BIO-X Open (previously reported to VINNOVA simply as BIO-X) is based on defined needs in healthcare and society. Its aim is to increase the flow of investable product or service concepts in the early stage of development.

BIO-X's unique combination of project database, clinical, industrial and academic networks, proximity to other incubators and demonstration environments plus a robust yet adaptable base in a quality-assured development and governance process is unparalleled in Sweden.

The programme enjoys high legitimacy within the industrial as well as academic and public sectors (healthcare and government agencies) and creates added value for all involved parties.

Within the framework of BIO-X Open, VINNOVA, following a recommendation from Uppsala BIO, approved eight projects (out of 53 applications) in the 2015 call 'ICT-healthcare solutions to improve personalised treatment and care'. These projects to develop patient-oriented products are supported for two years. The eight are:


- **Ingrid Carlbom, Uppsala university.** CMF surgery planning with the Uppsala Haptics-Assisted Surgery Planning system, HASP.
- **Rickard Färdig, EBP-Solutions.** iMRAPP – Supporting implementation of evidence-based psychosocial programs using mobile technology.
- **Jesper Hassel, Mevia.** Intelligent home care – Better support, improved patient care and lower societal costs.
- **Björn De Jonge, Biosync Technology.** Stress management solution for multiple sclerosis.

- **Pia Keyser, Brain Stimulation AB.** Diagnosis and rehabilitation after stroke.
- **Henrik Ljungberg, Medituner.** Self-management app supporting hands-on guidance for asthma.
- **Oliver Mohseni, Genit.** Genit – Handle with Care.
- **Tryggvi Thorgeirsson, GoodLifeMe.** Sidekick: A smartphone- and web-based tool for prevention and treatment of lifestyle disease.

In addition to these ICT projects, nine more projects from previous calls received BIO-X support during 2015. These are:

- **Gunnar Pejler, SLU.** Mast Cell Therapeutics.
- **Anna Schnürer, SLU.** Biogas microbial monitoring kit.
- **Mats Olsson, Park Cell.** Transplantation of a patient's skin cells into the brain to treat Parkinson's disease.
- **Cecilia Söderberg-Naucler, Karolinska Institutet.** Repositioning an existing drug for the treatment of HCMV infection and HCMV-positive cancers.
- **Sara Mangsbo, Uppsala University.** Development of a therapeutic vaccine to cancer based on the patient's own immune response.
- **Peetra Magnusson, Uppsala University.** Heparin conjugate for vascular protection.
- **Aman Russom, KTH.** New technology to combat blood poisoning: a diagnostic tool for early, rapid diagnosis of sepsis.
- **Christopher Holmström, Catheasy.** The Catheasy – method and device – Reduction of pain and prevention of bleeding and infection associated with changing urinary catheters.
- **Peter Löwenhielm, SP Technical Research Institute of Sweden.** Antibacterial and biocompatible polymers for prevention of surgical site infections.

In 2016, a number of recommended but not yet publically-announced projects will be added from the call 'New diagnostic solutions for disease monitoring'.



One of the most important indicators for evaluating BIO-X in the short term is additional investment, i.e. if the intention of making projects attractive for investment has been achieved. The above graph shows additional investments in 13 recently concluded BIO-X projects. Total funding after exit is 7.9-fold each invested BIO-X SEK. So far, Uppsala BIO has supported a hundred selected projects in the BIO-X Open programme. Of these, 36 were funded for approximately 70 MSEK.

In addition to the outcome of individual projects, the systemic change at regional and national level that occurs through the spread of BIO-X methodology is also important to take into account. For example, the National Strategic Innovation Agenda SWELife (see below) will base its calls on the BIO-X methodology from the autumn of 2015.

BIO-X INDUSTRY

The BIO-X Industry programme is based on BIO-X methodology as regards the screening and support of projects seeking an industrial partner. Projects included in BIO-X Industry receive help with screening, packaging and impartial assessment.

Many early commercialisation projects need funding, access to industry expertise, know-how and strategic input. At the same time, industry is on the lookout for early innovative projects with controlled levels of risk. By connecting screened innovation projects with industrial partners, BIO-X Industry can help leverage projects with suitable industrial players. Currently, Uppsala BIO has an agreement with Roche, who is seeking projects in the pharmaceutical field, and negotiations with an

additional industry player in another life science field are well advanced.

BIO-X Industry is based on outreach activities. Early commercialisation projects in the region are mapped on the basis of information available in the form of internal project databases, company reports, etc., that Uppsala BIO has built up. During the first year, the survey included around 100 projects in the pharmaceutical area, of which 40 have been in initial contact with the programme. About 20 projects have been packaged as a 'short proposal' and received an initial evaluation of business partners.

SWELIFE

As early as 2012, Uppsala BIO assumed a leading regional role in the preparatory work for and build-up of what became the Strategic Innovation Agenda SWELife. Similarly, in 2015 Uppsala BIO, along with several other early initiators, has been a driving force in developing new combinations of funding opportunities of both national scope and regional relevance. Thanks to a consensus between VINNOVA and the Swedish Agency for Economic and Regional Growth (Tillväxtverket), it is now possible to combine funding from SWELife with the European Regional Development Fund.

Uppsala BIO's participation in SWELife remains strong in other respects as well. Uppsala BIO employee Karin Agerman is a project manager and responsible for the C3 programme, where the open calls for proposals are based on Uppsala BIO's innovation program BIO-X. Uppsala BIO CEO Erik Forsberg is on the SWELife Board and County Governor Peter Egardt, president of Uppsala BIO's

Completed activities

parent organisation STUNS, is a member of SWElife's advisory board.

Notable 2015 SWElife activities include the following:

- The first call based on BIO-X methodology opened in November 2015. Uppsala BIO participates in the programme management.
- Implementation of a national model for standardised blood collection. The Regional Biobank Centre Uppsala-Örebro and Uppsala University are involved in the project. Means of support have been distributed to hospitals in five of the six health service regions.
- Verification support distributed to business incubators. Uppsala Innovation Centre is one of six incubators that have received funds from SWElife to distribute to companies.
- A new national funding structure proposed in the spring of 2015 is entirely in line with the report that the government's investigator Hans Rydstad submitted for consultation in June 2015.

NETWORKING ACTIVITIES

Various types of networking activities are another core activity of Uppsala BIO. By creating different venues, industry, government and universities meet and alliances or synergies arise.

Events organised by Uppsala BIO form the basis of these activities, including BIO-PUBs (PUB = Partnership University Business) and Efter Jobbet (after work) seminars. During 2015, four BIO-PUBs and seven Efter Jobbet seminars attracted a total of 571 attendees, of which 438 were unique visitors from 178 different organisations.

BIO-PUB

Evenings organised by Uppsala-BIO in collaboration with Connect in Uppsala. The focus is on short presentations from the evening's host (a member of Uppsala BIO or Connect) followed by mingling. The four hosts in 2015 were:

- Pharma Consulting Group, April 21
- UK Trade & Investment, May 28
- Uppsala Clinical Research Centre, October 6
- Swedish University of Agricultural Sciences (SLU), November 17

EFTER JOBBET

A series of seminars offering specialised insights into a currently topical issue. The seven seminars that were held in 2015 were:

- **What can be patented and how does one file a patent?** Brann AB, March 3
- **Statistical challenges in clinical trials** Statisticon, May 12
- **Social media** Andrew Hennigan, August 25
- **Establishing in the UK** UK Trade & Investment, September 21
- **Business secrets** Bergenstråhle & Partners, November 3
- **PR for the life science SMEs** Richard Hayhurst, November 23
- **The EU's Framework Programme for Research and Innovation** European Support Office, December 17

OTHER EVENTS

In addition to the internally arranged events mentioned above, Uppsala BIO also participated in NLSDays (Nordic Life Science Days), the largest partnering, investor and networking conference in life science, for the third year running. Twelve companies received support to attend the conference and present themselves on the shared Stockholm-Uppsala booth. During NLSDays, Uppsala BIO also gathered several innovation players together to provide investors and international stakeholders with a relevant and attractive image of the life sciences in the region. A campaign web site with articles on the participating companies was set up to serve the same purpose. Uppsala BIO was also very active in partnering meetings, mainly to build new relationships with industry stakeholders to develop the BIO-X Industry programme.

Moreover, in 2015 Uppsala BIO, along with companies from the region, participated in the international conferences AngloNordic, Genesis, BIO Convention and BIO Europe. (See also international activities below.)

PARTICIPATION IN BOARDS AND GROUPS

As part of the business intelligence activities and exchange of experiences on which Uppsala BIO's work is based, representatives from Uppsala BIO participate in various boards and steering groups. Examples include the Berzelii Center for Neuro-diagnostics, the OBOE Center for bioorganic electronics, the working group within the framework of the government's expert advisory panel, CEBR (Counsel of European Bioregions), EDCA (European Diagnostic Cluster Alliance), SciLifeLab Partnering and SWElife (see above). Uppsala BIO also participates in the national so-called ERFA-meetings run by VINNOVA's VINNVÄXT programme.

INTERNATIONAL ACTIVITIES

Since 2014, Uppsala BIO has continued to pursue part of the operations of the former Stockholm-Uppsala Life Science (SULS). During 2015, it focused on fact-based marketing and a special program for companies targeting contacts in the UK, UK.Links.

UK.Links has been run as a one-year pilot project with funding from VINNOVA and the Swedish Agency for Economic and Regional Growth with a view to helping the region's life science companies build bridges to the United Kingdom. The project has been separately accounted for at VINNOVA and the Agency for Economic and Regional Growth.

In addition to activities linked to UK.Links, Uppsala BIO has participated in a number of international conferences and forums. On several of these occasions, participating companies from the region were coached by Uppsala BIO in advance. To help achieve this, Uppsala BIO arranged a number of home events with an international theme, mainly as BIO-PUB and Efter Jobbet network events.

Uppsala BIO also engaged in international marketing in the form of media contacts and organising journalist visits. Overall, this work has resulted in about a dozen published editorial articles.

MEMBER ACTIVITIES

During 2015, work was conducted to expand and adjust the different types of offers available to members of the Uppsala BIO trade organisation. Current benefits include the opportunity to organise a BIO-PUB, to publish information and special offers, and receive assistance in public relations, etc. at trade fairs or other meetings both nationally and internationally.

In 2015, Uppsala BIO implemented and evaluated a pilot project on purchasing cooperation, the Uppsala BIO Purchasing Consortium. A purchasing consortium can generate lower purchasing costs and favourable supply conditions based on the collective buying power of the companies included in the consortium. In this pilot project, Uppsala BIO was responsible for the infrastructure, procurement and supplier contacts, including negotiations and contracts. The consortium companies then have direct contact with supplier for ordering, payment and continued business. In life science, this type of consortium has been pursued successfully for many years in Britain, the United States and other countries.

An internal evaluation of the pilot project proved positive and Uppsala BIO will formally launch the program in 2016. Decisions on the continuation and expansion of the project will be taken within the framework of the evaluation work Uppsala BIO 3.0 (see page 9).

EDUCATIONAL ACTIVITIES

Contacts with industry and business show that competence is a key factor for growth in the life science industry. Uppsala BIO thus makes targeted efforts at the interface between universities, government and business in order to support the supply of skills.

Although further education is the primary responsibility of municipalities, universities and other types of bodies, Uppsala BIO makes ongoing market-complementary efforts and creates value, particularly by linking the business community with schools.

PRESENTATIONS AND SEMINARS

By invitation, Uppsala BIO employees have given presentations or participated in job fairs for students at different levels on at least six occasions during 2015.

Completed activities

TECHNICAL COLLAGE

Uppsala BIO is a member of the Regional Steering Group for the Technical College. This is a form of collaboration where industry meets educators to ensure the availability of technical resources (engineers, practical secondary education and vocational colleges) to meet the needs of industry. In Uppsala's life science companies, process and production oriented staff are especially in demand (see also Regional activities / REBUS below).

In 2015, the Technical College Uppland implemented a certification process and was assessed by representatives of, among others, the Swedish Engineering Industries Association, IF Metall trade union, IKEM (Innovation and Chemical Industries in Sweden) and the Swedish Association of Graduate Engineers to ensure that it meets the stringent requirements imposed in order to bear the certificate Technical College. One key aspect has been the requirement to show that development goals set during the initial application three years ago have been followed.

A new Technical College graduate education started in 2015 at Fyrisskolan in Uppsala with a special focus on life science. Its work is currently under certification.

REGIONAL ACTIVITIES

One of STUNS' main tasks is to promote coherent innovation support, both regionally and nationally. Uppsala BIO operates in the same way by working with existing support and only initiating further measures where these are not available, or where they currently work less effectively.

A selection of more formalised collaborations and projects in 2015 is given below.

UPPSALA INNOVATION CENTRE

Uppsala BIO is the largest regional financier of Uppsala Innovation Centre (UIC). During the year, UIC was ranked as the fifth-best business incubator in Europe and the world's tenth best according to the UBI Global survey comparing 330 business incubators with a university connection spread over 63 countries. UIC's support for growth companies with international potential continued during 2015. Eighty-seven projects and companies participated a UIC business programme, of which 33 are active in life science.

Within the framework of Uppsala BIO's and UIC's agreement within the life sciences, the activities carried out in 2015 included:

- In January, UIC Business Start and UIC Business Agile were merged into a new program – UIC Business Startup. This program has continuous admissions and a total of 34 projects were adopted during the year. Seven of these were active in life science.
- Four rounds of the UIC Business Lab programme were completed in 2015, including three in Uppsala and one in Södertälje. In total, 31 projects / companies participated, of which 18 were in the life sciences.
- UIC Business Accelerator had 16 participating companies during the year, including eight in the life sciences.
- Ingrid Carlbom, as part of the HASP project included in BIO-X, participated in the UIC Business Startup.
- UIC shared a booth with Uppsala BIO at the Nordic Life Science Days conference together with Innovation Akademiska and Uppsala University Innovation.
- As in 2014, UIC had an article / advert in the latest issue of Life Science in Sweden, where UIC Södertälje and BIO-X were highlighted.

UPPSALA UNIVERSITY INNOVATION

Different types of collaboration are ongoing, including Uppsala University Innovation (UUI), whose director is a deputy member of SWElife's board. UUI and UIC assist Uppsala BIO as a hub within the framework of SWElife's calls. Uppsala contributes in the shape of SciLifeLab Partnering, which is primarily run by UUI and the Karolinska Institutet Innovation Office. In addition, Uppsala BIO also assists the Berzelii Center for Neurodiagnostics at Uppsala University, together with UUI.

SLU HOLDING

STUNS has participated in planning work for the Green Innovation Park and Uppsala BIO, together with SLU Holding and others, has applied for funding for the so-called 3i project (see page 11). In addition, Uppsala BIO has supported several BIO-X projects originating at SLU and has arranged a food-themed BIO-PUB.

CONNECT

During 2015, a number of BIO-X projects and some of Uppsala BIO's corporate members were offered the opportunity to participate in Connect's springboards, etc. Uppsala BIO has also participated in and contributed to an investment meeting focused on life sciences, where, among other things, a selection of projects from the springboards met an investor network. Uppsala BIO and Connect have together arranged four BIO-PUBs during 2015.

INNOVATION AKADEMISKA

Uppsala BIO assists Innovation Akademiska with resources. In 2015, this mainly took the form of support for projects seeking collaboration within municipal healthcare and nursing, including establishing processes and procedures for these collaborations. In addition, support to establish cooperation between Innovation Akademiska and Uppsala municipality and support to draw up contacts between industry and primary healthcare was also involved. The parent organisation STUNS also assisted Uppsala County Council in preparing an innovation strategy for healthcare in the county.

REBUS

REBUS stands for Reinforced relations between Business, Universities and Society. It was initiated by Uppsala BIO's principal STUNS during the second half of 2014 and will continue during 2016. REBUS is an outreach and relationship-building activity designed to identify gaps, obstacles and new opportunities for established life science companies' futures in Uppsala and Sweden. The overall purpose and objectives are the same as for Uppsala BIO and BIO-X. REBUS operates as an informal but highly result-oriented cooperation

between industry representatives and the founders' organisations, with Uppsala BIO playing a driving and unifying role.

Feedback is regularly reported to Uppsala BIO's steering committee and STUNS' evaluation group. Proposals for measures are submitted as appropriate and in consultation with the affected partners.

During 2015, the operational networks HR Network (training and access to skilled process operators in the life sciences) and Environment Network (environmental and permit issues) have both emerged. In addition, the Uppsala Life Science Network, a network with representatives from major life science companies in the region, is also actively run.

INVESTIGATIONS AND OTHER ACTIVITIES

Uppsala BIO 3.0 is a review of Uppsala BIO's activities. It was initiated in 2015 and will be conducted in parallel in coordination with Uppsala BIO's other operations during in 2016.

Given that the financial support from VINNOVA's Vinnväxt programme is being phased out, extensive work was initiated in 2015 to examine, evaluate and modify activities in such a way that their long-term financing can be secured. This work is called Uppsala BIO 3.0 and is headed by the STUNS CEO.

The aim of Uppsala BIO 3.0 is to achieve both a focus as well as a consolidation of business activities. Its goal is to by November 2016 at the latest, provide clearly motivated proposals for restructured operations in connection with a new business plan for Uppsala BIO and present this for decision to the Board of STUNS.

Organisation

BOARD

Uppsala BIO's Board of Directors convened four times in 2015. During the year, its business directive changed so that from 2016, the Board will be replaced by a steering committee.

The composition of Uppsala BIO's Board reflects the organisation's mandate under its operational directive. Board members' experiences range from large to small companies, research and development, entrepreneurship, business development, biomedical research, funding clinical research, healthcare, innovation policy and the ministerial issues. During 2015, the board consisted of the following persons:

- **Lars Hagel** (Chairman, previously GE Healthcare Bio-Science AB)
- **Martina Banyay** (Atlas Antibodies AB)
- **Jens Viebke** (Maquet Critical Care)
- **Sune Larsson** (Uppsala University Hospital)
- **Karin Forsberg Nilsson** (Uppsala University)
- **Jan Stenlid** (SLU)
- **Anki Bystedt** (Uppsala County Administrative Board / Stockholm University)

CO-WORKERS

To fulfil its mission, Uppsala BIO had 15 employees in 2015, three of whom were employed centrally within STUNS but financed by Uppsala BIO for special tasks within life science.

Five employees held 100 percent positions in 2015. Others worked part time in the range 20–70 percent. Five employees were men and ten women (33/67 percent).

- **Erik Forsberg**, CEO
- **Marie Skantz**, CFO (STUNS)
- **Annakarin Svenningsson**, Director of Communications
- **Anna Liljas**, Administrator

- **Karin Agerman**, Project manager BIO-X (Uppsala BIO and SWElife)
- **Ywonne Bölja**, Project manager Marketing (Uppsala BIO and Stockholm-Uppsala Life Science (SULS))
- **Kristin Hellman**, Project manager BIO-X and related projects (Uppsala BIO)
- **Frida Henningson Johnson**, Project manager Events and communication (Uppsala BIO)
- **Camilla Huse Bondesson**, Director of Business Development (Uppsala BIO)
- **Per Lundeqvist**, Business developer (STUNS)
- **Per Odebrant**, Writer, strategist (STUNS)
- **Erik Olaisson**, Project manager BIO-X (Uppsala BIO)
- **Kevan Reeve**, Business development, purchasing (Uppsala BIO)
- **Anna Ridderstad Wollberg**, Project manager BIO-X and related projects (Uppsala BIO)
- **Malin Wiederholm**, Product manager BIO-X (Uppsala BIO)

ADVISORY BOARDS

Members of Uppsala BIO's advisory boards support and guide BIO-X projects through their implementation phase and are hand-picked for their skills and areas of expertise.

In 2015, 38 people were engaged in the advisory boards, spanning a total of six different portfolios within BIO-X. The members' broad experience is spread over several areas of expertise such as industrial R&D, industrial business development, healthcare and other end-users, technology and science. Several of the 38 members have a skills profile that spans more than one area. Twenty-two men and 16 women (58/42 percent) were active in advisory boards during 2015.

Economic analysis

RESULT

Operational activities during 2015 encompassed more than 16 MSEK, to which can be added about 10 MSEK paid directly from VINNOVA to 14 different BIO-X projects. About 8 MSEK in in-kind contributions were also contributed by Uppsala BIO's co-financiers.

INCOME	Result (tkr)
Transferred funds from previous years	1,827
Contribution VINNVÄXT	6,000
Financiers' operating activities	5,730
Other income	3,368
Total income in 2015	16,925
EXPENDITURE	
<i>Registry</i>	
Personnel costs	8,400
Premises, telecommunications, IT, accounting, auditing, joint	1,702
Travel	100
Other expenses	218
Total registry	10,420
<i>Projects and programmes</i>	
Business development	1,875
Communication	1,062
Stockholm-Uppsala Life Science (SULS)	929
BIO-X/SIO-SWElife/UK Links/Univ/Companies	2,004
Total projects and programmes	5,870
TOTAL EXPENDITURE	16,290
Result	635

PARTICIPATION IN FUNDING APPLICATIONS

Uppsala BIO has participated during the year in three applications for funding:

1. SWElife East Central Sweden
(European Regional Development Fund, case ID 20200637)
2. 3i Innovation + Industry + Investment:
A collaboration platform for growth and regional equalisation
(European Regional Development Fund, case ID 20200636)
3. National platform for healthcare services at a distance
(the EU's national development fund, case ID 00191577).

All applications were granted.

Members and partners

Uppsala BIO works on behalf of all life science companies in the region. It has ongoing dialogues with member companies and can thus capture their needs and discuss ideas continuously. As a trade organisation, Uppsala BIO has 52 members. In 2015, it worked actively with recruitment and increased the number of members by 9 (20 percent). Members of Uppsala BIO are:

Acreo Swedish ICT AB	Denator AB	Kemwell AB	Uppsala Regional Council
Adecco	Devex	Kibion AB	Semcon AB
ALMI Företagspartner Uppsala AB	Double Bond Pharmaceuticals	Klövern	SLU <i>Swedish University of Agricultural Sciences</i>
AMO <i>Abbott Medical Optics</i>	Emplicure	Lidds AB	Statisticon AB
AroCell AB	Episentec AB	Mercodia AB	SVA <i>Swedish National Veterinary Institute</i>
Awapatent	Equalis AB	Moreinx AB	Thermo Fisher Scientific
Beactica	Galderma <i>(Q-Med AB)</i>	Novavax	Uppsala Innovation Centre
Bergenstråhle	GE Healthcare Bio-Sciences AB	Olink AB	Uppsala Municipality
Biotage AB	Gradientech	OnTarget Chemistry AB	Uppsala University
Brann	Uppsala County Chamber of Commerce	Orexo AB	Uppsala University Hospital
Connect Uppsala*	Hureka Resources	Pelago Bioscience AB	VINNOVA
Crown CRO	Index Pharmaceuticals	Pharma Consulting Group AB	
CTC <i>Clinical Trial Consultants AB</i>	InfoTech Scandinavia AB	Dfind Science and Engineering <i>(formerly Proffice)</i>	
DanPET AB		redhot diagnostics AB	

*Connect Uppsala has a special cooperation agreement rather than a member agreement.